Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B, and urokinase plasminogen activator in non-skull base chordoma.

Abstract

We analyzed the expression of proteases and the clinicopathologic significance in non-skull base chordoma (NSBC). By using immunohistochemical techniques, we studied the expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B (CatB), and urokinase plasminogen activator (uPA) in 29 NSBCs and compared these data with clinicopathologic parameters and the expression of cell differentiation markers. Expression of MMP-1 (P = .092), MMP-2 (P = .041), and CatB (P = .058) was associated with nuclear pleomorphism, a previously described adverse prognostic indicator. Expression of cytokeratin 8 correlated with that of MMP-1 (P = .005), MMP-2 (P = .002), and uPA (P = .032). Patients with higher MMP-2 expression had a poorer prognosis than those with lower MMP-2 expression (P = .013). We believe that NSBCs with nuclear pleomorphism or stronger epithelial character have a higher invasive ability than those without. In addition, high MMP-2 expression was an indicator of an unfavorable clinical outcome in NSBC.

• Authors: Takahiko Naka, Carsten Boltze, Doerthe Kuester, Torss-Oliver Schulz, Amir Samii, Christian Herold, Helmut Ostertag, Albert Roessner
• Journal: American journal of clinical pathology (Am J Clin Pathol) Vol. 122 Issue 6 Pg. 926-30 (Dec 2004) ISSN: 0002-9173 [Print] England
• PMID: 15539385 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Keratins
• Urokinase-Type Plasminogen Activator
• Cathepsin B
• Matrix Metalloproteinases

Topics

• Adult
• Aged
• Aged, 80 and over
• Bone Neoplasms (enzymology, mortality, pathology)
• Cathepsin B (biosynthesis)
• Chordoma (enzymology, mortality, pathology)
• Humans
• Immunohistochemistry
• Keratins (metabolism)
• Matrix Metalloproteinases (biosynthesis)
• Middle Aged
• Prognosis
• Survival Analysis
• Urokinase-Type Plasminogen Activator (biosynthesis)